Endocrine Abstracts

Background: Glucagon-like peptide-1 (GLP-1) is secreted from L cell at a small intestine and decreases blood glucose by stimulating insulin secretion. Therefore, GLP-1 receptor antagonists (GLP1-RA) is used to treat type 2 diabetes mellitus. In addition to the hypoglycemic effect, GLP-1 has been reported to reduce heart disease and renal dysfunctions. GLP-1 action on the kidneys is a natriuretic effect. Therefore, it may have a renoprotection effect. However, it is unknown whe...